CDB Leasing (01606): Jin Tao resigns as Vice Chairman, Executive Director, and President of the company.
Industrial and Commercial Bank of China Gold Leasing (01606) announced that Mr. Jin Tao has resigned from the positions of Vice Chairman, Executive Director, President, Chairman of the Social Responsibility and Consumer Rights Protection Committee of the Board, Member of the Board Remuneration Committee, Member of the Board Related Party Transaction Control Committee, Member of the Board Risk Management and Internal Control Committee, and Member of the Board Strategic Decision Committee due to work adjustment, effective from March 18, 2026.
CDB Leasing (01606) announced that Mr. Jin Tao has resigned from his positions as Vice Chairman, Executive Director, President, Chairman of the Board's Corporate Social Responsibility and Consumer Rights Protection Committee, member of the Board's Compensation Committee, member of the Board's Related Party Transaction Control Committee, member of the Board's Risk Management and Internal Control Committee, and member of the Board's Strategic Decision-making Committee, due to work adjustments, effective from March 18, 2026.
Related Articles

BEISEN HOLDING (09669) spent HK$363,600 on March 18th to buy back 81,200 shares.

LAEKNA-B is expected to achieve revenues of approximately 107 million yuan in 2025, with a year-on-year increase in research and development expenses of 16.17%.

TRANSTHERA-B (02617): The first patient in Phase II clinical trial of combination of Enzalutamide and Fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer patients who have failed prior treatments has completed dosing.
BEISEN HOLDING (09669) spent HK$363,600 on March 18th to buy back 81,200 shares.

LAEKNA-B is expected to achieve revenues of approximately 107 million yuan in 2025, with a year-on-year increase in research and development expenses of 16.17%.

TRANSTHERA-B (02617): The first patient in Phase II clinical trial of combination of Enzalutamide and Fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer patients who have failed prior treatments has completed dosing.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


